In yesterday’s Wall Street session, ImmunityBio Inc (NASDAQ:IBRX) shares traded at $6.17, up 3.01% from the previous session.
IBRX stock price is now 40.93% away from the 50-day moving average and 98.88% away from the 200-day moving average. The market capitalization of the company currently stands at $4.16B.
With the price target reduced from $10 to $4, Piper Sandler Downgraded its rating from Overweight to Neutral for ImmunityBio Inc (NASDAQ: IBRX). On August 03, 2022, Jefferies recently initiated its ‘Buy’ rating on the stock quoting a target price of $8
In other news, BLASZYK MICHAEL D, Director bought 71,915 shares of the company’s stock on Jun 05 ’23. The stock was bought for $198,023 at an average price of $2.75. Upon completion of the transaction, the Director now directly owns 71,915 shares in the company, valued at $0.44 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 02 ’23, Director Brennan John Owen bought 25,000 shares of the business’s stock. A total of $70,700 was incurred on buying the stock at an average price of $2.83. This leaves the insider owning 25,000 shares of the company worth $0.15 million. A total of 80.43% of the company’s stock is owned by insiders.
During the past 12 months, ImmunityBio Inc has had a low of $1.25 and a high of $6.93. The fifty day moving average price for IBRX is $4.42 and a two-hundred day moving average price translates $3.12 for the stock.
The latest earnings results from ImmunityBio Inc (NASDAQ: IBRX) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$0.35, missing analysts’ expectations of -$0.18 by -0.17. This compares to -$0.27 EPS in the same period last year. The company reported revenue of $0.14 million for the quarter, compared to $73000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 90.41 percent. For the current quarter, analysts expect IBRX to generate $20k in revenue.
